Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients...

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer who develop VTE may be at an increased risk...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), was able to be administered safely in patients...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at five years in patients with beta-thalassemia, when the transplant...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results from the U.K. National Cancer Research Institute’s Myeloma XI...

Ropeginterferon Alfa-2B Versus Hydroxyurea in Patients With Polycythemia Vera

Treatment with ropeginterferon alfa-2B, a mono-pegylated proline interferon, reduced JAK2 allele burden in patients with polycythemia vera (PV) and appeared to modify the underlying...

Fostamatinib Improves Platelet Counts in Certain Patients With Heavily Pretreated ITP

In a phase II study published in Blood, the oral SYK inhibitor fostamatinib was safe and effective in a cohort of 16 patients with...

Evaluating a Risk-Adapted Treatment Approach in Younger Patients With AML

A risk-adapted approach incorporating minimal residual disease (MRD) and cytogenetic data could help identify patients with acute myeloid leukemia (AML) who would benefit from...

Danazol Plus ATRA Safe and Effective in Corticosteroid- Resistant/Relapsed ITP

According to results from a multicenter, prospective study presented at the 22nd Congress of the European Hematology Association, the combination of all-trans retinoid acid...

CC-122 Plus Obinutuzumab Effective in Relapsed/Refractory B-Cell NHL

Combining the anti-CD20 monoclonal antibody obinutuzumab with the first-in-class pleiotropic pathway modifier CC-122 led to high response rates and durable remissions in patients with...

Updated Results From ZUMA-1 Show “Promising” Response Rates With CAR T-Cell Therapy in ...

Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a high objective response rate (ORR) in patients with relapsed/refractory non-Hodgkin...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.